Application of FGF10 in preparation of lung injury diagnosis reagent

Abstract

The invention discloses an application of FGF10 in preparation of a lung injury diagnosis reagent. What is found for the first time is that the combination of FGF10, especially FGF10, YKL-40 protein and AFP-L3, can be used as a diagnostic marker for diagnosing lung injury, especially chronic obstructive pneumonia, and the detection specificity of chronic obstructive pneumonia can be effectively improved.

Description

technical field [0001] The invention belongs to the field of medical detection, in particular to the application of FGF10 in preparing reagents for diagnosing lung injury. Background technique [0002] Respiratory system disease is a common and frequently-occurring disease. The main lesions are in the trachea, bronchi, lungs, and chest cavity. Mild cases often cause coughing, chest pain, and respiratory problems. Severe cases have dyspnea, hypoxia, and even death due to respiratory failure. The death rate in the city is the third, while in the countryside it is the first. What should be paid more attention to is that due to air pollution, smoking, population aging and other factors, chronic obstructive pulmonary disease (referred to as COPD, including chronic bronchitis, emphysema, pulmonary heart disease), bronchial asthma, lung cancer, The morbidity and mortality of diseases such as pulmonary diffuse interstitial fibrosis and pulmonary infection have increased unabated. ...

AI Technical Summary

Problems solved by technology

[0005] At present, the pathogenesis of COPD has not been fully elucidated, and it is generally believed that the chronic inflammation of the airway, lung parenchyma, and pulmonary blood vessels caused by inflammatory cells such as neutrophils and macrophages causes the characteristic changes of COPD.

In addition, protease-antiprotease imbalance, oxidative stress, etc. are also closely related to the occurrence and development of COPD, so COPD-related biomarkers are divided into: (1) Inflammatory biomarkers, including inflammatory cells and inflammatory factors , such as neutrophils, macrophages, interleukin (interleukin, IL) family, etc., such as IL-2, IL-4, IL-6, etc. Although these markers have strong sensitivity, their specificity is poor; ( 2) Biological markers of protease and anti-protease, such as extracellular matrix protease (Matrix Metalloproteinase, MMP)-8, MMP-9, etc.; (3) Pulmonary-derived markers, such as pulmonary surfactant protein (surfactantprotein, SP)-D , Clara cell protein (Claracellprotein, CC) 16, chemokine ligand (CCChemokineLigand, CCL)-18, etc.

The detection results of the latter two types of markers in patients' serum and in alveolar lavage fluid are quite different, so it is necessary to conduct further research on the markers of COPD

Images